流感季提前到来，奥司他韦7天销量飙升237%

Core Insights - The article highlights a significant increase in flu activity in China, with the flu season arriving earlier than usual, leading to a surge in demand for antiviral medications such as Oseltamivir and Baloxavir [1][4][5]. Group 1: Flu Activity and Demand for Medications - The Chinese Center for Disease Control and Prevention (CDC) reported that flu activity has entered a rapid rise phase, with many provinces experiencing moderate to high levels of flu activity [1][4]. - Sales of Oseltamivir have surged by 237% in the past week, while Baloxavir sales increased by 180% [1][4]. - The current flu season is characterized by a predominance of the H3N2 subtype, with a significant increase in respiratory symptoms and a higher risk of pneumonia [4][5]. Group 2: Market Dynamics of Antiviral Drugs - The antiviral drug market is evolving, with Oseltamivir historically dominating the market but facing increased competition from generic versions and new entrants [8][9]. - Oseltamivir's market share has decreased since the expiration of its patent, with nearly 140 related drug approvals by November 2025 [8]. - New antiviral drugs targeting flu virus RNA polymerase are entering the market, with significant sales growth expected for Baloxavir, projected to exceed 10 billion yuan by 2025 [8][9]. Group 3: Treatment and Public Awareness - Clinical experts emphasize the importance of early treatment with antiviral medications within 48 hours of symptom onset to reduce the severity and duration of the illness [6][12]. - There is a common misconception among the public that flu is the same as a common cold, which can lead to delays in seeking appropriate treatment [12][13]. - Preventive measures such as wearing masks and maintaining social distance are recommended to curb the spread of the flu [12][13].